Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke

ASPECTS indicates Alberta Stroke Program Early CT Score; CRP, C-reactive protein; DWI, diffusion-weighted imaging; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; NGSP, National Glycohemoglobin Standardization Program; NIHSS, National Institute of Health Stroke Scale; and pc-ASPECTS, posterior circulation-Alberta Stroke Program Early CT Score.
*Abnormality of coagulation, arterial dissection, vasculitis, or undetermined.

IQR indicates interquartile range; LDL-C, low-density lipoprotein cholesterol; and NIHSS, National Institutes of Health Stroke Scale.

ALT indicates alanine aminotransferase; AST, aspartate transaminase; CK, creatine kinase; and ULN, upper limit of normal range.
*Gallbladder cancer, pancreatic cancer, and gastric cancer.
†Clinically worsened stroke or deterioration of NIHSS score of ≥4 points.
‡Low back pain, lower extremity myalgia, ankle sprain, knee arthrosis, and shoulder subluxation.
§Asthma, left atrial myxoma, dehydration, hypokalemia, and hypertrophic obstructive cardiomyopathy.

Authors and Disclosures

Shinichi Yoshimura, MD, PhD, Kazutaka Uchida, MD, Takashi Daimon, PhD, Ryuzo Takashima, BA, Kazuhiro Kimura, PhD and Takeshi Morimoto, MD, PhD, MPH, on behalf of ASSORT Trial Investigator*

Department of Neurosurgery (S.Y., K.U.), Department of Clinical Epidemiology (K.U., T.M.), Center for Clinical Research and Education (T.D., T.M.), and Department of Biostatistics (T.D.), Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; and Medical Affairs Department, Shionogi & Co, Ltd, Osaka, Japan (R.T., K.K.).

Guest Editor for this article was Seemant Chaturvedi, MD.
*A list of all ASSORT Trial Investigators is given in the Appendix.
Presented in part at the International Stroke Conference, Houston, TX, February 24, 2017.

Correspondence to
Takeshi Morimoto, MD, PhD, MPH, Department of Clinical Epidemiology, Hyogo College of Medicine, 1–1 Mukogawa, Nishinomiya, Hyogo 663–8501, Japan. E-mail t-morimoto@umin.net

Disclosures
Dr Yoshimura disclosed the research grants from Shionogi & Co, Ltd, Terumo, Takeda, and Bristol-Meyers and honoraria from Mitsubishi Tanabe Pharma, Sanofi, Bristol-Meyers, Boehringer-Ingelheim, Otsuka Pharmaceutical, Bayer, Daiichi Sankyo, and Pfizer. Dr Daimon disclosed honoraria from Astellas Pharma, Chugai Pharmaceutical, Daiichi Sankyo, Ono Pharmaceutical, and Terumo and served as a consultant for Ajinomoto and Eisai. R. Takashima and Dr Kimura are employees of Shionogi & Co, Ltd. Dr Morimoto disclosed honoraria from AstraZeneca, Daiichi Sankyo, and Pfizer and served as a consultant for Boston Scientific. The other author reports no conflicts.

Appendix

ASSORT Trial Investigators: Shinichi Yoshimura, Kazutaka Uchida, Takeshi Morimoto, Takashi Daimon, Ryuzo Takashima, Kazuhiro Kimura, Shuichi Tanada, Tomoko Iida, Junko Kuroda, Akinori Nose, Kotaro Tatebayashi, Fuminori Shimizu, Shun Tsudaka, Masataka Takeuchi, Nagayasu Hiyama, Yoshiharu Oki, Joji Hagii, Shin Saito, Tsuyoshi Matsumoto, Yasue Tanaka, Yoji Kuramoto, Kazuyuki Mikami, Narihide Shinoda, Daisuke Shimo, Junichi Soneda, Kou Tokuda, Kenichi Matsuda, Kakita Hiroto, Ikuya Yamaura, Takashi Okada, Teruyuki Hirano, Naoya Kuwayama, Satoshi Teramukai. The role and affiliation are presented in the online only Data Supplement.